Introduction
============

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder, characterized by a degeneration of upper and lower motor neurons leading to a progressive muscular paralysis. Although median survival most often averages 3--4 years, the large variability of its course ([@awy152-B7]) raises an urgent need to develop biomarkers able to characterize the mechanisms underlying disease progression and to improve the diagnostic yield of clinical and neurophysiological evaluation.

Most studies in this setting focused on cortical response to ALS. Among these approaches, brain PET studies with ^18^F-fluorodeoxyglucose (FDG) already reported a significant reduction in glucose metabolism ([@awy152-B22]) in motor and premotor cortex ([@awy152-B13]; [@awy152-B1], [@awy152-B2]). By contrast, involvement of the spinal cord has been characterized in relatively lower detail, mostly because of the anatomical features of this structure that limit the standardization of its evaluation. Consequently, a large uncertainty still exists about the mechanisms underlying ALS-induced damage in the spinal cord and its relationship with cortical impairment. We recently reported the potential of the Hough transform in delineating spinal cord structure and metabolic activity in a population of ALS patients subjected to FDG PET/CT ([@awy152-B17]). Specifically, this classical pattern recognition approach for the automatic identification of straight lines in the image has been recently extended to the recognition of more complex shapes. This computational 3D approach enabled the extraction of spinal cord metabolic information from whole body images and permitted us to document increased glucose consumption, possibly representing a potential and independent prognostic marker ([@awy152-B17]).

In the present study, we simultaneously analysed brain and spinal cord FDG uptake in a series of prospectively recruited patients submitted to brain and whole-body PET/CT.

Materials and methods
=====================

Patients with amyotrophic lateral sclerosis
-------------------------------------------

The study included 44 prospectively recruited patients with definite, probable or probable laboratory-supported ALS diagnosis according to the revised El-Escorial criteria ([@awy152-B6]). None of them had any history of other neurological disorders, cerebrovascular disease, diabetes mellitus or systemic inflammatory disease. All subjects provided signed informed consent to enter the study that was approved by the Ethics Committees of IRCCS Ospedale Policlinico San Martino in Genoa, and of AUO Città della Salute e della Scienza in Turin, Italy.

Control subjects
----------------

Brain PET from patients with ALS were compared with the corresponding data of 44 healthy volunteers who gave their informed consent. As described by [@awy152-B20], their healthy condition was carefully checked by means of clinical and neuropsychological examination, brain MRI and by the same exclusion criteria as used for ALS patients. A case--control criterion was adopted to reproduce the same age range, gender distribution and educational level of ALS patients.

For ethical considerations, PET/CT scan was not extended to the body of these normal volunteers. Accordingly, PET spinal cord data were compared with the corresponding findings of 44 control subjects without any history of neurodegenerative disease, randomly selected from a previously published normalcy database ([@awy152-B23]), again according to a case--control criterion.

PET/CT imaging
--------------

All PET/CT scans were acquired according to current guidelines ([@awy152-B25]) as detailed in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

Spinal cord analysis
--------------------

The entire CT dataset was co-registered with the 3D PET images using commercially available software interfaces. Image analysis was performed by means of a pattern recognition algorithm based on an extension of the Hough transform to algebraic curve. As described in the [Supplementary material](#sup1){ref-type="supplementary-material"}, this approach uses an operator-independent fully deterministic algorithm to identify the spinal canal and to extract spinal cord FDG uptake expressed as standardized uptake value (SUV) according to the method previously validated in our laboratory, which is described elsewhere ([@awy152-B23]; [@awy152-B5]; [@awy152-B19]).

The cervical spinal cord segment was defined as the region between skull basis and the plane adjacent to the caudal face of C7 vertebral body. Dorsal segment was defined as the district included between this plane and the one adjacent to the caudal face of D12. Lumbar and sacral canal districts were *a priori* excluded.

Brain PET analysis
------------------

Statistical Parametric Mapping (SPM) analysis was performed as previously described ([@awy152-B20]) and detailed in the [Supplementary material](#sup1){ref-type="supplementary-material"}. To compare ALS effects on global consumption of brain and spinal cord, SPM analysis of FDG uptake distribution was complemented with the evaluation of absolute tracer retention. Accordingly, the preprocessed NifTI-1 PET images were converted in whole-brain SUV parametric maps dividing the product between radiotracer concentration (kBq/ml) and body weight (in kg) by the injected FDG dose (in MBq) ([@awy152-B8]; [@awy152-B18]; [@awy152-B3]). Thereafter, WFU PickAtlas and NiftyReg were used to automatically identify volumes of interest corresponding to 41 Brodmann areas (BAs) in both hemispheres. All data are reported as mean ± standard deviation (SD). Unpaired or paired *t*-tests were used, as appropriate. *P*-values \< 0.05 were considered significant. Analyses were performed using SPSS package (version 21).

Results
=======

Clinical characteristics of patient population
----------------------------------------------

As reported in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, age, sex, and ideal body weight were similar in control and ALS subjects. ALS Functional Rating Scale Revised (ALSFRS-R) score, updated at imaging date, was 39 ± 4 (range 28--45). Mean time elapsed from clinical disease onset and PET/CT scanning was 20 ± 15 months (range 8--81 months, median 14 months) while mean interval between ALS diagnosis and imaging was 10 ± 9 months.

Spinal cord metabolism
----------------------

FDG uptake was significantly higher in the whole spinal cord of ALS patients with respect to controls (0.81 ± 0.4 versus 0.67 ± 0.2, *P =*0.05). This difference was more pronounced in cervical segments (1.08 ± 0.2 versus 0.82 ± 0.2, *P \<*0.01) and relatively less evident in dorsal metameres (0.69 ± 0.2 versus 0.57 ± 0.2, *P \<*0.05). Effect of ALS on spinal cord metabolism was independent from demographic and clinical variables as well as from time elapsed from diagnosis to imaging. Likewise, spinal cord metabolic activation was similar in spinal or bulbar onset ALS. Yet, the regional agreement between increased FDG uptake and clinical motor impairment could be documented in the 33/35 spinal patients in whom predominantly upper (*n =*12) or lower (*n =*21) limb involvement was well defined at diagnosis ([Fig. 1](#awy152-F1){ref-type="fig"}). Upper limb onset was associated with a more pronounced metabolic activation in the cervical segment ([Fig. 1](#awy152-F1){ref-type="fig"}). The selectivity of this metabolic response was confirmed by the ratio between cervical and dorso-lumbar spinal cord tracer retention that was significantly higher in patients with upper limb clinical onset ([Fig. 1](#awy152-F1){ref-type="fig"}). By contrast, the difference in FDG uptake of caudal spinal cord did not reach the statistical significance in patients with lower limb involvement ([Fig. 1](#awy152-F1){ref-type="fig"}).

![**Spinal cord metabolism in upper and lower limb clinical onset.** (**A** and **C**) 3D reconstructions of spinal cord FDG uptake, in a patient with upper or lower ALS onset, respectively. (**B**) The corresponding SUV values plotted from cervical slices (*top*) to lumbar ones (*bottom*). Tracer retention is higher in cervical segments in upper limb presentation, while the reverse gradient occurs in lower limb onset. (**D**) Average SUV values in the two spinal cord districts: in patients with upper limb onset tracer uptake in the cervical spinal cord is higher with respect to both the dorsal segment in the same patients and with respect to the same segment in the remaining subjects. This selective localization is confirmed by the ratio cervical/dorso-lumbar tracer uptake reported in **E**. ns = not significant; SC = spinal cord.](awy152f1){#awy152-F1}

SPM analysis of amyotrophic lateral sclerosis effect on brain FDG distribution
------------------------------------------------------------------------------

SPM-based group analysis highlighted a wide hypometabolic cluster involving frontal dorso-lateral cortex bilaterally as well as the precentral and temporal cortex in the left hemisphere ([Fig. 2](#awy152-F2){ref-type="fig"}A and [Table 1](#awy152-T1){ref-type="table"}). Conversely, hypermetabolic cluster was markedly smaller and mainly involved the midbrain ([Fig. 2](#awy152-F2){ref-type="fig"}B and [Table 1](#awy152-T1){ref-type="table"}). This metabolic pattern was reproduced in spinal as well as in bulbar onset patients. Bulbar onset was instead associated with a more severe metabolic impairment in bilateral precentral gyri (BA 6) and in left putamen ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). Table 1SPM analysis**Cluster levelPeak levelCluster ExtentCorrected *P*-valueCortical regionMaximum Z-scoreTalairach coordinates *x*, *y*, *z*Cortical regionBACortical regions of relative hypometabolism**13570.0001L-limbic5.48−33 −9 −34Uncus20L-limbic5.35−36 −18 −26Uncus20L-temporal4.78−45 −22 −21Fusiform gyrus2016190.0001L-frontal5.06−49 1 45Middle frontal gyrus6L-frontal4.97−32 15 51Superior frontal gyrus8R-frontal4.5815 30 49Superior frontal gyrus8**Cortical regions of relative hypermetabolism**3840.01R-frontal5.1911 −19 −13Superior frontal gyrus8R-sublobar4.7423 −8 −8AmygdalaR-sublobar3.8313 −2 0Lentiform nucleusR-sublobar3.5036 −9 16Insula133790.01R-midbrain4.697 −18 −19**Correlation between cervical spinal cord and brain metabolism**3490.01L-frontal4.13−5 −40 57Paracentral lobule5R-frontal4.1115 −24 69Precentral gyrus4L-frontal3.62−5 −30 56Paracentral lobule6**Correlation between dorsal spinal cord and brain metabolism**4090.01R-sublobar4.7542 −7 16Insula13R-sublobar3.5541 4 12Insula13R-sublobar3.3934 −14 15Claustrum3470.01L-frontal4.46−13 23 49Superior frontal gyrus6L-limbic3.79−7 17 37Cingulate gyrus32L-limbic3.48−5 0 42Cingulate gyrus245900.01L-sublobar4.07−34 −9 15Insula13L-sublobar3.49−36 −2 23Insula13L-frontal3.30−41 6 36Precentral gyrus94360.01L-frontal3.55−49 35 18Middle frontal gyrusL-frontal3.16−25 34 21Medial frontal gyrus9L-frontal3.14−31 30 32Middle frontal gyrus9

![**SPM analysis.** 3D rendering showing regions in which FDG uptake was significantly lower (**A**) or higher (**B**) in ALS patients with respect to controls. (**C** and **D**) Results of the multiple regression analysis between brain and cervical or dorsal spinal cord metabolism, respectively. Threshold *P \<*0.05, corrected for multiple comparisons with the FDR at the voxel level were set in each analysis. Coordinate and regional details are presented in [Table 1](#awy152-T1){ref-type="table"}.](awy152f2){#awy152-F2}

Among the 35 patients with spinal ALS, right onset was associated with a more severe metabolic impairment in the left premotor cortex (BA 6) and in the left temporal cortex (BA 39) as well as in the right postcentral gyrus (BA 3) ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). By contrast, no appreciable difference in brain metabolism was identified between ALS patients classified according to upper or lower limb clinical onset (data not shown).

Mean SUV of cervical spinal cord was significantly and inversely correlated with hypometabolism in the pre- and para-central gyri bilaterally but particularly in the left hemisphere ([Fig. 2](#awy152-F2){ref-type="fig"}C and [Table 1](#awy152-T1){ref-type="table"}). Similarly, dorsal spinal cord mean SUV predicted a relative hypometabolism in the temporo-lateral and frontal dorso-lateral cortex in the left hemisphere ([Fig. 2](#awy152-F2){ref-type="fig"}D and [Table 1](#awy152-T1){ref-type="table"}). Finally, neither cervical nor dorsal spinal cord metabolism were significantly correlated with midbrain metabolic pattern.

Volumes of interest analysis
----------------------------

FDG uptake, estimated by average SUV of automatically identified volumes of interest, was significantly lower in ALS patients with respect to controls in virtually all analysed BAs ([Fig. 3](#awy152-F3){ref-type="fig"}). As a consequence, this same observation also applied when the average SUV of the whole cortical volume was considered (4.93 ± 1.40 versus 5.95 ± 1.65, respectively, *P \<*0.01). Similarly, ALS was associated with lower SUV in thalamus (5.31 ± 1.76 versus 6.4 ± 1.7, respectively, *P \<*0.01), basal ganglia (6.17 ± 1.75 versus 7.2 ± 2.0, respectively, *P \<*0.01) and cerebellum (3.1 ± 1.98 versus 5.6 ± 1.5, respectively, *P \<*0.01).

![**Volumes of interest analysis.** BA SUV values in ALS (filled bars) and control subjects (open bars) according to cortical lobes. The *y*-axes represent BA SUV values. Yellow = frontal lobe; green = parietal lobe; blue = occipital lobe; pink = temporal lobe. \**P \<*0.05; \*\**P \<*0.01.](awy152f3){#awy152-F3}

Discussion
==========

The main finding of the present study is the divergent metabolic response to ALS in brain and spinal cord. Brain displays a generalized reduction in glucose consumption particularly evident in motor and premotor cortex. By contrast, spinal cord displays a moderate increase in FDG uptake that can be more easily detected in its cervical segment. The interplay between the two opposite metabolic patterns, documented by this transversal and simultaneous picture, indicates a divergent nature or a divergent time-course of the mechanisms underlying ALS-related damage to upper and lower motor neurons.

In agreement with our previous observation ([@awy152-B17]), the analysis of spinal cord metabolic pattern showed a significant increase in FDG uptake in the spinal cord of ALS patients. The reproducibility of this finding and its occurrence in a cohort of prospectively and independently recruited ALS subjects confirm that 'metabolic spinal cord activation' might occur in a high number of ALS patients and might thus track pathophysiological mechanisms potentially contributing to disease progression. This concept is corroborated by the observation that, among spinal onset ALS patients, upper limb presentation was associated with a more pronounced metabolic activation of cervical spinal cord. This finding thus suggests that spinal cord metabolic activation might track some process related to motor impairment on a regional basis. Actually, the opposite pattern was not observed in patients with lower limb involvement most likely because of the limited spatial resolution hampering the evaluation of caudal spinal cord because of contaminations related to both partial volume effect and uncertainty in the definition of caudal spinal cord border.

On the other hand, SPM analysis of brain FDG distribution confirmed previous studies in larger numbers of patients reporting small areas of relative hypermetabolism virtually limited to the midbrain and large hypometabolic clusters in the frontal dorso-lateral cortex ([@awy152-B8]; [@awy152-B22]) with the uncus involved only in our series. Accordingly, the simultaneous coupling of both evaluations provided a new and, under many points of view, unexpected glance at available data about ALS metabolic effect on the CNS.

Currently, SPM is one of the most widely used standards to evaluate brain FDG images. In conventional 'static' PET studies, this procedure analyses the original reconstructed data reporting radioactivity concentration (in kBq/ml) in each voxel. These source images are thus scaled to an intracranial reference region to identify areas of relative activation (hypermetabolism) or stilling (hypometabolism). However, scaling procedure intrinsically prevents the capability to identify generalized reductions in brain glucose consumption. Indeed, several authors argued about the interpretation of voxelwise-highlighted hypermetabolic clusters that might reflect a true metabolic activation as well a relatively less severe metabolic deceleration in neurodegenerative disorders ([@awy152-B18]).

To overcome this limitation, and to replicate the analysis criteria adopted for spinal cord evaluation, we processed the original data of tracer concentration to calculate average SUV in each automatically detected volume of interest. Obviously, this procedure does not account for both FDG persistence in the circulating blood and competition by serum glucose level. Nevertheless, its capability to abolish the interference of the main methodological determinants of tracer uptake---administered dose and body weight---permitted us to detect a generalized reduction of FDG uptake in studied ALS patients.

This finding confirms previous dynamic PET studies that reported a generalized and progressive reduction of glucose consumption in ALS brain partially related to disease duration ([@awy152-B9]), degree of cognitive decline ([@awy152-B16]) or severity of upper motor neuron involvement ([@awy152-B11]). Similarly, localization of metabolic impairment, provided by voxelwise analysis, closely agrees with the thinning of the primary motor cortex previously documented by MRI in ALS patients ([@awy152-B26]) and also with recent ([@awy152-B10]) and older neuropathological studies reporting abnormalities not only in the Betz area ([@awy152-B14]) but also in the adjacent gyri and in the deeper parts of the brain ([@awy152-B24]). Unfortunately, the lack of coregistered PET and MRI images prevents the possibility to define whether the reduced tracer uptake in hypometabolic areas reflects a reduced density of cells with an intact metabolism, a reduced metabolic rate of glucose consumption by normal populations of synapses or both mechanisms. Nevertheless, the same analytical approach documented that the metabolic activation of spinal cord faced a global impairment in glucose consumption involving the vast majority of encephalic structures.

The mechanisms underlying this opposite response cannot be identified by the present data. Nevertheless, post-mortem studies document the activation of microglia ([@awy152-B4]), oligodendrocytes ([@awy152-B15]) and astrocytes ([@awy152-B21]) in tissues harvested from motor cortex and spinal cord of both ALS patients and experimental models of ALS. In particular, astrocytic activation nicely fits with the notion that these cells account for most of the FDG accumulation in the brain ([@awy152-B27]). Defining these mechanisms is obviously far beyond the scope of this clinical and observational study. Nevertheless, the divergent pattern of FDG uptake in the spinal cord and brain indicates that the metabolic response of these two districts follows different pathways or different time sequences. Accordingly, monitoring the temporal evolution of damage in the first and in the second motor neuron might represent an important clue to improve our understanding of ALS pathophysiology.

Obviously, a direct estimation of brain glucose consumption would have provided a more detailed description of metabolic pattern in both brain and spinal cord ([@awy152-B12]). Ethical concerns prevented the possibility to perform a complex series of acquisitions with dynamic sequence followed by brain and whole-body scans. Nevertheless, the decreased FDG uptake in the brain, together with the opposite response of spinal cord SUV, strongly support the concept that hypermetabolic brain clusters identified by SPM analysis probably reflect areas of relatively preserved glucose consumption rather than the consequence of neuronal activation ([@awy152-B22]).

As a main limitation of our study, brain and spinal cord metabolic patterns of ALS patients were compared with normalcy databases harvested from different populations. In brain-image donors, this limitation was justified by the ethical concern in extending CT scan to the whole body of normal volunteers. For normal spinal cord evaluation, the ethical concern was related to the need to avoid modifications to the standard protocol of oncologic imaging that does not include the pre-scan procedure needed for cerebral PET/CT. As a further limitation, the limited patient sample and the relatively wide inclusion criteria did not permit us to verify any possible correlation between degree/site of spinal cord metabolic activation and force generated by the related muscular districts. A similar consideration applies to the side coherence between brain metabolism and motor involvement. Actually, when compared with left onset, right onset ALS was associated with a more severe metabolic impairment in the left hemisphere. However, this finding must be interpreted cautiously because of the possible occurrence of several biases related to the limited sample size and the variable side with most prominent symptoms at time of scan.

In conclusion, the present transversal and observational study documents a divergent metabolic response to ALS by spinal cord and brain. This evidence indicates that whatever mechanism affects glucose consumption of the CNS in ALS, its nature or its time course profoundly differ in upper and lower motor neurons. This divergent behaviour indicates that complementing brain imaging with the extraction of spinal cord information might improve the informative potential of PET studies with tracers selectively interrogating specific pathophysiological mechanisms underlying ALS progression.
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